UroGen Pharma Ltd. (URGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

UroGen Pharma Ltd. (URGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

LOS ANGELES, June 6, 2025 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to UroGen Pharma Ltd. ("UroGen" or the "Company") (NASDAQ: URGN) have opportunity to lead the securities fraud class action lawsuit.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN UROGEN PHARMA LTD. (URGN), CLICK HERE BEFORE JULY 28, 2025 (THE LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

 What Is The Lawsuit About?
The complaint filed alleges that, between July 27, 2023 and May 15, 2025, Defendants failed to disclose to investors that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (2) as a result, the Company would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (3) UroGen failed to heed the FDA's warnings about the study design used to support a drug application for UGN-102; (4) as a result of the foregoing, there was a substantial risk that the NDA for UGN-102 would not be approved; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us.
The Law Offices of Frank R. Cruz, 
Email us at: info@frankcruzlaw.com
Call us at: 310-914-5007
Visit our website at: www.frankcruzlaw.com
Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you inquire by email, please include your mailing address, telephone number, and number of shares purchased.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View original content:https://www.prnewswire.com/news-releases/urogen-pharma-ltd-urgn-investors-who-lost-money-have-opportunity-to-lead-securities-fraud-lawsuit-302474910.html

SOURCE The Law Offices of Frank R. Cruz, Los Angeles